| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO | Director +1 more
2 companies
Shenouda Maged is a Chief Financial Officer at RLMD, with reported holdings spanning 2 companies. Recent filings cover 19 purchases and 18 sales. Those positions are worth an estimated $4.3M at current prices.
Our model assigns Shenouda Maged a middling insider score of 52/100, based on 12 past trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -7.3%.
Shenouda Maged's largest disclosed position is in RLMD as Chief Financial Officer, worth about $4.3M. Net of sales, the recent Form 4 record there shows accumulation of 967,750 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 200,000 | $4.22 | $843,990.00 | +25.0% | - | - | |
| Dec 15, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 11,665 | $4.12 | $48,059.80 | +1.5% | +41.7% | - | |
| Nov 5, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 500,000 | $2.20 | $1,100,000.00 | +173.4% | +51.4% | - | |
| May 20, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 200,000 | $0.49 | $97,208.00 | +226.4% | +11.2% | +1101.0% | |
| Sep 11, 2024 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 53,432 | $2.80 | $149,700.84 | +153.1% | -84.4% | -49.7% | |
| Jan 31, 2024 | RLMD Relmada Therapeutics, Inc. | Chief Financial Officer | Buy | 32,675 | $3.85 | $125,716.68 | +1,467% | -7.4% | -91.0% | |
| Mar 10, 2021 | RLMD Relmada Therapeutics, Inc. | CFO | Sale+OE | 10,000 | $35.45 | $354,506.63 | -81.8% | -13.8% | -35.7% | |
| Feb 24, 2021 | RLMD Relmada Therapeutics, Inc. | CFO | Sale+OE | 3,000 | $34.18 | $102,529.24 | -57.4% | - | - | |
| Feb 11, 2021 | RLMD Relmada Therapeutics, Inc. | CFO | Sale+OE | 1,428 | $35.39 | $50,542.06 | -39.1% | - | - | |
| Feb 10, 2021 | RLMD Relmada Therapeutics, Inc. | CFO | Sale+OE | 11,372 | $35.17 | $399,910.17 | -83.6% | - | - |